|
|
||||||||
| ABSTRACT |
|
|
|---|
| INTRODUCTION |
|
|
|---|
WNV is transmitted by many species of mosquitoes and uses a variety of birds as amplifying hosts.4,5 Although the vector and host competency of North American mosquitoes and birds are known to some extent, there are too few observations on the host competency of mammals to exclude them from being involved in the transmission cycle.68 Experimental infections of horses, dogs, and cats indicate that these species are either dead-end or poorly competent hosts.9,10 At least some rodents are competent hosts.11 However, little is known about the host competency of common mammalian wildlife in North America.12 Because of the considerable investment involved in experimental infection studies, the most economical approach to determine a species role in transmission is to survey wildlife populations for their risks of exposure to the virus. Once high-risk species are identified, their host competency can be tested experimentally. Identification of competent hosts and vectors is critical to understand the ecology of WNV and the factors important in driving disease cycles, and, by implication, forecasting temporal and spatial risks to human populations.13,14
Sera collected from white-tailed deer (Odocoileus virginianus) during wildlife control operations and hunter-harvests in Iowa from 1999 to 2003 provided an opportunity to determine the deers exposure to flaviviruses in general, and WNV and Saint Louis encephalitis virus (SLEV) specifically. Herein, we show that WNV is commonly transmitted to white-tailed deer and that this species should be further examined for its role in WNV transmission cycles. The utility of white-tailed deer as a surveillance indicator species also is discussed.
| MATERIALS AND METHODS |
|
|
|---|
Indirect enzyme-linked immunosorbent assay (iELISA). A WNV iELISA was used to screen for flavivirus-specific immunoglobulin G (IgG) antibodies.15 This method may detect cross-reactive antibodies raised against other flaviviruses, thus it was viewed as a general screening method for flavivirus antibody detection.15
Positive and negative antigens were provided by New York State Department of Healths Wadsworth Center.16,17 Antigen was diluted (1:200) in coating buffer (0.015 M NaCO3, 0.035 M NaHCO3, pH 9.6) and applied (50 µL/well) to the inner wells of a 96-well plate (Costar, Corning Incorporated, Corning, NY). Negative antigen was placed in every third column and positive antigen was placed in the remaining columns. Antigen binding to the wells was achieved by placing plates in a humidified chamber (plastic bag with a damp paper towel) and incubating (4°C) them overnight. After incubation, antigen solutions were discarded and wells washed (3x) with PBS-T (0.01 M phosphate buffer, 0.138 M NaCl, 0.0027 M KCl, pH 7.4 with 0.05% Tween 20). Next, blocking buffer (PBS-T with 2% casein) was added (200 µL/well) and plates were incubated (37°C, 1 hour) in a humidified chamber. Blocking buffer was discarded, and test sera diluted in PBS-T with 0.5% bovine albumin (PBS-T-BA) (1:100 dilution) were added (50 µL/well) to duplicate wells. Five known negative control deer sera (PRNT90 less than 1:10), one known positive control deer serum (PRNT90 greater than 1:10), and one blank (buffer only) were included in each plate. Plates were incubated (37°C, 1 hour) in a humid chamber and after sera were discarded, washed (3x) with PBS-T. After incubation, horseradish peroxidase conjugated rabbit anti-deer immunoglobulin IgG (Kirkegaard & Perry Laboratories, Inc., Gaithersburg, MD), diluted 1:100 in PBS-T-BA, was added (50 µL/well) and incubated (37°C, 1 hour). After incubation, the conjugate solution was discarded and the plates were washed (3x) with PBS-T and developed at room temperature (7 minutes) with tetramethylbenzidine (TMB)-peroxidase substrate (Kirkegaard & Perry Laboratories, Inc.) (50 µL/well). The reaction was stopped by adding (50 µL/well) H2PO4 diluted 1:5.
Optical density (OD) was read at a wavelength of 450 nm. Samples were considered positive if OD values were
3 standard deviations above the mean (OD = 0.055) of negative-control samples from 25 white-tailed deer (PRNT less than 1:10). Positive controls were obtained from 5 deer infected with WNV in Iowa (PRNT greater than 1:10) (National Veterinary Services Laboratories, Ames, IA), 3 deer infected with WNV in New York City (PRNT 1:10) (New York State Diagnostic Laboratory), and from 4 reindeer (> 90% inhibition by blocking ELISA) vaccinated (West Nile-Innovator vaccine, Fort Dodge Animal Health, Wyeth corporation) at the Denver Zoo, Denver, Colorado.
Epitopeblocking enzyme-linked immunosrobent assay (bELISA). A bELISA using the monoclonal antibody (MAb) 3.112G was used to detect immunoglobulin M (IgM) and IgG antibodies against WNV.18,19 This assay is specifically reactive to WNV, offers a high degree of sensitivity, and enables the assay to be taxon-independent in its ability to detect antibodies against the NS-1 epitope of WNV.18
WNV antigen was diluted (1:200) in coating buffer (see above) and applied (100 µL/well) to the inner 60 wells of a 96-well plate. The plate was placed in a humidified chamber and incubated (4°C) overnight. The next morning, the antigen solution was discarded, plates were washed (4x) with PBS-T, and blocking buffer (PBS with 5% skim milk) was added (200 µL/well) to each well. Plates then were incubated (37°C, 40 minutes), after which blocking buffer was discarded and the plates were washed (4x). Fifty microliters of test samples, diluted (1:10) in blocking buffer, were added to each well and incubated (37°C, 2 hours). The test samples were then discarded, plates were washed (4x), and MAb 3.1112G (Chemicon Intern, Temecula, CA) diluted in blocking buffer (1: 2,000) was added (50 µL/well) and incubated (37°C, 1 hour). After removal of MAb solution, plates were washed (4x) and horseradish peroxidaseconjugated rabbit anti-mouse IgG (Zymed Laboratories, San Francisco, CA) (1:2,000 dilution) was added (50 µL/well) and incubated (37°C, 1 hour). After removal of conjugate solution, plates were washed (4x). ABTS substrate (2,2' azinobis [3-ethylbenzthiazoline-6-sulfonic acid]) and peroxidase solutions from the ABTS Microwell peroxidase substrate system (KPL, Gaithersburg, MD) were mixed 1:1, and were added (75 µL/well). Optical density (OD) values were read at 415 nm in an automated plate reader.
Percent inhibition of MAb binding was calculated using the formula18 100 [(TS B)/(CS B)] x 100, where TS is the OD of test serum, CS is the OD of negative control serum, and B is the background OD. The percent inhibition was calculated once the control serum OD values exceeded 0.3. An inhibition value of
30% was considered positive for the presence of anti-WNV antibodies.19
Plaque reduction neutralization test (PRNT).
Differential diagnosis for antibody positive samples was confirmed by plaque reduction neutralization test (PRNT) against WNV and SLEV.19,20 Heat-inactivated samples (56°C, 30 minutes) were serially diluted twofold in BA-1 (Hanks M-199 salts, 50 mM Tris [pH 7.6], 1% bovine serum albumin, 0.35 g of sodium bicarbonate/L, 100 units of penicillin/mL, 50 µg of gentamicin/mL, 2.5 µg fungizone/mL), starting at a dilution of 1:5. Diluted serum (100 µL) was mixed (1:1) with additional diluent containing approximately 200 PFU (plaque forming units) of virus and incubated (4°C) overnight. Each serum-virus suspension (100 µL) was inoculated onto confluent Vero cell monolayers in six-well plates and incubated (37°C, 60 minutes). Overlay medium (MEM supplemented with 5% fetal bovine serum, 0.5% agarose, and antibiotics as in BA-1) was added (2 mL/well for WNV, and 3 mL/well for SLEV) and the plates were incubated (37°C: 2 days for WNV; 5 days for SLEV), after which a second overlay containing 0.004% neutral red was added. Plaques were counted 24 to 48 hours after the second overlay, and titers expressed as the reciprocal of the highest dilution of the serum that yielded
90% reduction in the number of plaques (PRNT90).
Statistical tests.
Data were analyzed by
2 and the binomial difference between proportions tests.
| RESULTS |
|
|
|---|
2 = 0.4, P = 8.17). The prevalence of antibodies against flaviviruses increased to 23.3% and 31.9% of the sampled population during 2002 and 2003, respectively (Figure 1A
= +20.1%) represented a 628% increase in flavivirus antibody prevalence between the years 2001 and 2002 (P < 0.001). Deer populations continued to show an increase (36.9%) in prevalence of antibodies against flaviviruses in the subsequent year (cf. 2002 versus 2003;
= +8.6%, P = 0.041).
|
|
Prevalence of neutralizing antibodies to WNV and SLEV as determined by PRNT.
None of the samples positive by iELISA (N = 19) prior to 2002 was positive by WNV PRNT90 or SLEV PRNT90 (Table 1
). Nor were any of the 2002 and 2003 iELISA positive samples positive by SLEV PRNT90. The prevalence for neutralizing antibodies against 188) and 8.5% (N = 186) WNV (PRNT90) was 7.9% (N = for 2002 and 2003, respectively. The values from the PRNT80 (Table 1
) assay were were statistically identical to those estimated by bELISA. The difference in prevalence estimates by iELISA and bELISA indicate an unknown flavivirus was circulating in deer populations prior to 2002, and that an increase in unknown flavivirus transmission occurred concurrently with WNV transmission in 2002 and 2003 (Figure 1C
).
The sensitivity of the iELISA compared with PRNT90 was 98.18% and its specificity was 93.03%. The sensitivity of the bELISA compared with PRNT90 was 58.18% and its specificity 98.72%.
There were no differences in antibody prevalence between males and females in 2002 (Z = 0.016; P = 0.98) and 2003 (Z = 1.585; P = 0.113) by PRNT90 (Table 1
). There also was no association between age and positive WNV serology in 2002 (
2 = 5.74; P = 0.057) and 2003 (
2 = 3.26; P = 0.196) by PRNT90 (Table 1
). Prevalence for the naive age class, fawns, indicates that the annual exposure to WNV was around 5%.
| DISCUSSION |
|
|
|---|
The detection of WNV-specific antibodies in white-tailed deer during 20022003 was consistent with other reports of WNV activity in the area. The prevalence as determined by WNV-specific bELISA and WNV-PRNT90 were concordant. The slightly higher prevalence found by PRNT90 over bELISA, while not statistically different, may be attributable to differing efficiencies of the two assays in detecting neutralizing versus non-neutralizing antibodies.18,19,25 Because the samples were obtained in the winter months, 3 to 4 months after the mosquito season was over, it is possible that a higher concentration of neutralizing antibodies was present in the sera. It may also be possible that because the bELISA uses a MAb targeted against an epitope in the NS1 protein, whereas antibody measured by PRNT is primarily directed against E protein epitopes, that the difference in prevalence may reflect a bias in response against these two proteins.
The antibody negative results found by bELISA and WNV PRNT90 for 19992001 were expected because the first WNV case in Iowa (a dead crow) was reported in September 2001 in eastern Iowa, when the mosquito season was already ending.3 The prevalence of antibodies by these WNV-specific assays during 20022003 was consistent with other estimates of viral activity in the area (Table 2
). More interesting was evidence of transmission of a non-WNV, non-SLEV flavivirus prior to the appearance of WNV in Iowa, and the dramatic increase in transmission of the(se) flavivirus(es) during 2002 and 2003. The increase in prevalence of the undescribed flavivirus in 2002 and 2003 suggests that environmental conditions favoring overall flavivirus transmission occurred coincidentally with the WNV epizootic. What these factors might have been remains to be determined. There is evidence for the circulation of other flaviviruses in the United States5,26 (e.g., the newly discovered tick-borne encephalitis-like virus provisionally named "deer tick virus," similar to Powassan virus27,28). Moreover, serological cross-reactions between flaviviruses and pestiviruses also have been demonstrated.29
|
Although the antibody prevalences to WNV found in this study confirm WNV exposure in deer, there are no indications what effects WNV might have on the health of deer populations. However, transmission of WNV to white-tailed deer does occur, and it now remains to be determined through experimental infection studies their susceptibility, mortality, and reservoir potential to WNV. This information will lead to a better understanding of the role this species has in the ecological cycle of WNV.
In summary, we have provided serologic evidence for WNV infection in white-tailed deer from Iowa. These results are consistent with human, veterinary, and bird cases reported in Iowa. Even though human case reports are good sources of information to detect activity of a virus in a region, sometimes these reports can be inaccurate because of difficulty in establishing a precise geographic area of exposure and because asymptomatic people do not get tested. Serologic surveillance studies in domestic animals are also useful but have problems because of the introduction of vaccines for WNV. In contrast, surveillance studies of white-tailed deer can provide an accurate, rapid, cost-effective, and easy way to monitor the activity of WNV in a region.
Received April 7, 2005. Accepted for publication July 11, 2005.
Acknowledgments: The authors thank the Iowa Department of Natural Resources for collecting and providing sera specimens for serological analysis. The authors thank Dr. Mitchell Palmer at the National Animal Disease Center, Ames, Iowa, Dr. Felicia Knightly at the Denver Zoo, and Dr. Amy Glazer at the New York State Diagnostic Laboratory for providing control samples. The authors thank Kevin Bentler for kindly providing assistance in the laboratory. The authors thank Dr. Hector Jaime Aricapa at Caldas University for helpful comments and critical review of the study proposal. This study complies with the Principles of Animal Care, publication no. 86-23, revised 1985, of the National Institutes of Health and with current laws of the United States of America. This study was conducted under quality assurance protocol QA-1086 as part of the research project "Wildlife Diseases: Surveillance, Monitoring, Research, and Response" at the National Wildlife Research Center.
Financial support: Funding for this study was provided by the National Wildlife Research Center, Fort Collins, Colorado.
* Address correspondence to Jeffrey S. Hall, United States Department of Agriculture, Animal and Plant Health Inspection Service, Wildlife Services, National Wildlife Research Center, Fort Collins, CO 80521-2154. E-mail: Jeffery.S.Hall{at}aphis.usda.gov ![]()
Authors addresses: Julian Santaella, Robert McLean, Jeffrey S. Hall, and Larry Clark, United States Department of Agriculture, Animal and Plant Health Inspection Service, Wildlife Services, National Wildlife Research Center, Fort Collins, CO 80521-2154, Telephone: (970) 266-6137, Fax: (970) 266-6138. James S. Gill, University Hygienic Laboratory, University of Iowa, Iowa City, IA. Richard A. Bowen, Colorado State University, Fort Collins, CO 80521. Harlo H. Hadow, Biology Department, Coe College, Cedar Rapids, IA 52402.
Reprint requests: Larry Clark, United States Department of Agriculture, Animal and Plant Health Inspection Service, Wildlife Services, National Wildlife Research Center, Fort Collins, CO 80521-2154, Telephone: (970) 266-6137, Fax: (970) 266-6138, E-mail: Larry.Clark{at}aphis.usda.gov.
| REFERENCES |
|
|
|---|
This article has been cited by other articles:
![]() |
C. H. King and M. Dangerfield-Cha The unacknowledged impact of chronic schistosomiasis Chronic Illness, March 1, 2008; 4(1): 65 - 79. [Abstract] [PDF] |
||||
![]() |
K. T. BENTLER, J. S. HALL, J. J. ROOT, K. KLENK, B. SCHMIT, B. F. BLACKWELL, P. C. RAMEY, and L. CLARK SEROLOGIC EVIDENCE OF WEST NILE VIRUS EXPOSURE IN NORTH AMERICAN MESOPREDATORS Am J Trop Med Hyg, January 1, 2007; 76(1): 173 - 179. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J. ROOT, P. T. OESTERLE, N. M. NEMETH, K. KLENK, D. H. GOULD, R. G. MCLEAN, L. CLARK, and J. S. HALL Experimental infection of fox squirrels (sciurus niger) with west nile virus. Am J Trop Med Hyg, October 1, 2006; 75(4): 697 - 701. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |